NCT03847909 - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

June 21, 2021

Study Completion Date

June 29, 2021

Conditions

Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney DiseasesUrologic DiseasesGenetic Disease

Interventions

DRUG

DCR-PHXC

Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo

Trial Locations (28)

2807

Clinical Trial Site, Beirut

3052

Clinical Trial Site, Parkville

4029

Clinical Trial Site, Herston

10016

Clinical Trial Site, New York

15224

Clinical Trial Site, Pittsburgh

38320

Clinical Trial Site, Santa Cruz

53127

Clinical Trial Site, Bonn

55905

Clinical Trial Site, Rochester

69120

Clinical Trial Site, Heidelberg

75019

Clinical Trial Site, Paris

94143

Clinical Trial Site, San Francisco

9103102

Clinical Trial Site, Jerusalem

02115

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Hamilton

Clinical Trial Site, Bron

Clinical Trial Site, Beirut

Clinical Trial Site, Auckland

Clinical Trial Site, Bialystok

Clinical Trial Site, Bucharest

Clinical Trial Site, Birmingham

Clinical Trial Site, London

00165

Clinical Trial Site, Roma

467-8601

Clinical Trial Site, Nagoya

329-0431

Clinical Trial Site, Tochigi

183-8561

Clinical Trial Site, Tokyo

1105 AZ

Clinical Trial Site, Amsterdam

08035

Clinical Trial Site, Barcelona

WCIN 3JH

Clinical Trial Site, London